Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2527331 | Clinical Therapeutics | 2012 | 26 Pages |
Abstract
The addition of linagliptin to SU therapy for 18 weeks in these patients with T2DM was associated with statistically significant and clinically meaningful reductions in HbA1c compared with placebo. The overall tolerability of linagliptin was similar to that of placebo, with a low risk for hypoglycemia and no significant weight gain. These findings support the use of linagliptin as adjunctive therapy in patients with T2DM inadequately controlled on SU monotherapy. ClinicalTrials.gov identifier: NCT00819091.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Andrew J. MD, Lisa MBA, Dacheng PhD, Sanjay MB, ChB, Maximilian MD, Hans-Juergen MD,